INLIGHT Phase 1 data continue to support WVE-007’s novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen Six-month data from ongoing Phase 2a monotherapy trial in individuals with high BMI, high adiposity, and comorbidities anticipated in 2027 WVE-007/tirzepatide combination trial ongoing; Wave announces plan to integrate its maintenance clinical trial with this ongoing combination trial CAMBRIDGE, Mass

Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs) Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation Ongoing generation of translational data demonstrating that DNase I enhanced antitumor activity across four CAR targets in preclinical models o

Teleconference and Webcast to be held on November 17, 2026 PRINCETON, N.J. , Nov. 13, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 17, 2026, at 11:00 a.m. ET. The conference call will provide an update on corporate an

iStock, z_wei When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market. Rival drugmaker woes, discontinued programs and upcoming make-or-break readouts were just a few of the storylines that emerged from a busy week of biotech earnings . Below, BioSpace recaps earnings for four biotechs in the news. Arrowhead, Ionis face uphill battle in severe hypertriglyceridemia

iStock, Gugurat Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration. The Department of Health and Human Services is full steam ahead on ibogaine. On Thursday, the department announced a range of investments in the psychedelic compound, along with other rapid-acting psychotropic drugs for serious mental illnesses, including post-traumatic stress disorder. Up to $4.9 million will be invested through the

Positive recommendation is based on phase III ALLEGORY study data showing Gazyva/Gazyvaro significantly reduced disease activity in patients with SLE compared with placebo 1 If approved, Gazyva/Gazyvaro would be the first glycoengineered, Type II anti-CD20 therapy for SLE, potentially becoming the new standard of care SLE, commonly known as lupus, is a potentially life-threatening autoimmune disease that frequently leads to recurrent flares, progressive organ damage and requires long-term steroi

Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared updated long-term efficacy data for both relutrigine and ulixacaltamide Outlined plans to extend ulixacaltamide into Parkinson’s disease, Restless Legs Syndrome, and Autism Spectrum Disorder, with studies initiating in 2027 Introduced a broadened pipeline with multiple assets in Pain, KCNT1 DEEs and the Solidus ™ antisense oligonucleotide (ASO) Platform

Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit TRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly after PPD pivotal program — initiation targeted for H2 2027 Vanina Popova, MD, appointed Chief Development Officer — Formerly Clinical Development at J&J, lead author of pivotal Spravato® trial publication Cash, cash equivalents and marke

Expanding scientific rationale for Ampligen ® in the evolving pancreatic cancer treatment landscape, including potential complementary approaches with RAS-targeted therapies Ampligen dosing completed in Phase 2 DURIPANC study, positioning Company for near-term clinical benefit readout that could help shape pivotal Phase 3 development Primary Phase 2 endpoint analysis expected to begin in December 2026, with topline results anticipated in Q1 2027 and additional median overall survival and immune

PRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended September 30, 2026. “During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted I